BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
Clinical trial NCT01305551 · WITHDRAWN
Trial details
- NCT number
- NCT01305551
- Sponsor
- AstraZeneca
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-01
- Primary completion
- 2011-03-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.